Published in J Virol on January 01, 2006
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol (2008) 3.79
Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest (2010) 1.91
Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nat Commun (2015) 1.66
Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature (2014) 1.57
Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res (2007) 1.50
Recombinant adeno-associated virus transduction and integration. Mol Ther (2008) 1.44
Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol (2008) 1.44
Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology (2010) 1.41
RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J Gene Med (2010) 1.38
AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice. Mol Ther (2009) 1.22
Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther (2010) 1.21
Adeno-associated virus vector integration. Curr Opin Mol Ther (2009) 1.20
AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice. Gene Ther (2012) 1.12
Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice. Mol Ther (2011) 0.96
Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo. Hum Gene Ther (2007) 0.95
Sexually dimorphic patterns of episomal rAAV genome persistence in the adult mouse liver and correlation with hepatocellular proliferation. Mol Ther (2009) 0.93
A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration. Hum Mol Genet (2015) 0.87
Structural Insights into the Assembly of the Adeno-associated Virus Type 2 Rep68 Protein on the Integration Site AAVS1. J Biol Chem (2015) 0.87
Immunoadhesins containing pre-S domains of hepatitis B virus large envelope protein are secreted and inhibit virus infection. J Virol (2007) 0.86
Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus. Curr Protoc Microbiol (2013) 0.85
Creating a novel origin of replication through modulating DNA-protein interfaces. PLoS One (2010) 0.84
Reducing the risk of adeno-associated virus (AAV) vector mobilization with AAV type 5 vectors. J Virol (2009) 0.84
Targeting adipose tissue via systemic gene therapy. Gene Ther (2014) 0.84
Gene transfer of apolipoprotein A-V improves the hypertriglyceridemic phenotype of apoa5 (-/-) mice. Arterioscler Thromb Vasc Biol (2013) 0.79
Biochemical and Physiological Improvement in a Mouse Model of Smith-Lemli-Opitz Syndrome (SLOS) Following Gene Transfer with AAV Vectors. Mol Genet Metab Rep (2014) 0.79
Systemic Delivery of scAAV8-Encoded MiR-29a Ameliorates Hepatic Fibrosis in Carbon Tetrachloride-Treated Mice. PLoS One (2015) 0.78
Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors. Mol Ther Methods Clin Dev (2016) 0.76
Gene transfer in the lung using recombinant adeno-associated virus. Curr Protoc Microbiol (2012) 0.76
Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods (2017) 0.75
Plasmodium berghei EXP-1 interacts with host Apolipoprotein H during Plasmodium liver-stage development. Proc Natl Acad Sci U S A (2017) 0.75
Relevance of assembly-activating protein for Adeno-associated virus vector production and capsid protein stability in mammalian and insect cells. J Virol (2017) 0.75
Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs. Mol Ther Nucleic Acids (2017) 0.75
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A (2002) 11.11
Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol (2004) 7.12
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol (1996) 6.22
Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol (1996) 5.94
Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell (1983) 5.27
Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet (1997) 4.72
Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol (1998) 4.71
Gene therapy vectors based on adeno-associated virus type 1. J Virol (1999) 4.63
Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A (2000) 4.39
Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol (1998) 4.17
Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol (2004) 3.65
Factors that bind to adeno-associated virus terminal repeats. J Virol (1989) 3.56
Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol (2001) 3.38
Cloning and characterization of adeno-associated virus type 5. J Virol (1999) 3.36
Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A (2003) 3.31
Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol (2005) 3.28
Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem (1993) 3.02
Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol (1997) 2.91
AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 2.81
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood (2003) 2.74
Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein. J Virol (1993) 2.69
Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther (2003) 2.49
The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol (2002) 2.44
Biology of adeno-associated virus. Curr Top Microbiol Immunol (1996) 2.40
Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet (2004) 2.27
Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol (2000) 2.26
Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood (2003) 2.21
From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther (2003) 2.12
Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood (2005) 2.12
Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol (2005) 2.09
Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther (2005) 2.08
Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol (2000) 2.00
Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc Natl Acad Sci U S A (1997) 1.91
Sequence and symmetry requirements within the internal palindromic sequences of the adeno-associated virus terminal repeat. Virology (1988) 1.88
Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology (2004) 1.88
Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol (1999) 1.84
A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol (2005) 1.79
Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood (2001) 1.74
Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. Mol Ther (2001) 1.74
Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther (1999) 1.73
A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol (2002) 1.71
A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med (2000) 1.68
Characterization of the transcription profile of adeno-associated virus type 5 reveals a number of unique features compared to previously characterized adeno-associated viruses. J Virol (2002) 1.64
Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression. J Virol (2001) 1.58
A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol (1997) 1.57
Structural analysis of adeno-associated virus transduction circular intermediates. Virology (1999) 1.56
Adeno-associated virus (AAV) type 5 Rep protein cleaves a unique terminal resolution site compared with other AAV serotypes. J Virol (1999) 1.55
Chromosomal effects of adeno-associated virus vector integration. Nat Genet (2002) 1.47
Cloning and characterization of a bovine adeno-associated virus. J Virol (2004) 1.46
Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol (2000) 1.39
Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles. J Virol (2003) 1.37
Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J Virol (2001) 1.29
Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and Rep proteins. J Virol (1997) 1.28
Adeno-associated virus type 2 DNA replication in vivo: mutation analyses of the D sequence in viral inverted terminal repeats. J Virol (1997) 1.27
Production methods for gene transfer vectors based on adeno-associated virus serotypes. Methods (2002) 1.23
Two independent molecular pathways for recombinant adeno-associated virus genome conversion occur after UV-C and E4orf6 augmentation of transduction. Hum Gene Ther (1999) 1.23
Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J Virol (2005) 1.21
Consequences of DNA-dependent protein kinase catalytic subunit deficiency on recombinant adeno-associated virus genome circularization and heterodimerization in muscle tissue. J Virol (2003) 1.16
Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol (2005) 1.14
Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. Mol Ther (2003) 1.08
Pathways of removal of free DNA vector ends in normal and DNA-PKcs-deficient SCID mouse hepatocytes transduced with rAAV vectors. Hum Gene Ther (2003) 1.02
Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo. Hum Gene Ther (2005) 1.01
Transposase-mediated construction of an integrated adeno-associated virus type 5 helper plasmid. Biotechniques (2002) 1.00
Double strand interaction is the predominant pathway for intermolecular recombination of adeno-associated viral genomes. Virology (2003) 0.99
Free DNA ends are essential for concatemerization of synthetic double-stranded adeno-associated virus vector genomes transfected into mouse hepatocytes in vivo. Mol Ther (2003) 0.95
Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. Hum Gene Ther (2005) 0.88
A genetic screen identifies a cellular regulator of adeno-associated virus. Proc Natl Acad Sci U S A (2001) 0.85
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet (2003) 6.95
RNA interference in adult mice. Nature (2002) 5.33
Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol (2007) 5.04
Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther (2006) 4.64
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2002) 4.60
A nonviral minicircle vector for deriving human iPS cells. Nat Methods (2010) 4.42
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A (2012) 4.20
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol (2008) 3.79
Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Nat Struct Mol Biol (2009) 3.70
Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol (2004) 3.65
Human tRNA-derived small RNAs in the global regulation of RNA silencing. RNA (2010) 3.40
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol (2005) 3.28
Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol (2003) 3.15
High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol (2005) 3.10
Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther (2003) 2.95
The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol (2006) 2.94
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest (2011) 2.83
AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 2.81
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood (2003) 2.74
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol (2002) 2.54
Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther (2003) 2.49
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol (2002) 2.31
Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol (2005) 2.09
Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther (2005) 2.06
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 2.05
Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther (2008) 2.01
Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol Cell Biol (2004) 1.97
Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest (2010) 1.91
The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing in vivo. Cell (2012) 1.84
Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circ Res (2012) 1.84
Site-directed transposon integration in human cells. Nucleic Acids Res (2007) 1.74
A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol (2002) 1.71
Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther (2009) 1.71
Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A (2012) 1.60
Adenovirus transduction is required for the correction of diabetes using Pdx-1 or Neurogenin-3 in the liver. Mol Ther (2007) 1.51
Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. Mol Ther (2002) 1.51
Intraganglionic AAV6 results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats. PLoS One (2013) 1.51
Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol Ther (2007) 1.51
Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther (2008) 1.49
Novel minicircle vector for gene therapy in murine myocardial infarction. Circulation (2009) 1.45
Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. Mol Ther (2003) 1.42
Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology (2010) 1.41
Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol Ther (2007) 1.40
In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther (2002) 1.39
Nonhomologous-end-joining factors regulate DNA repair fidelity during Sleeping Beauty element transposition in mammalian cells. Mol Cell Biol (2003) 1.37
Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant (2010) 1.36
The role of DNA-PKcs and artemis in opening viral DNA hairpin termini in various tissues in mice. J Virol (2007) 1.35
Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest (2007) 1.34
Capped small RNAs and MOV10 in human hepatitis delta virus replication. Nat Struct Mol Biol (2008) 1.34
In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest (2003) 1.33
Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem (2008) 1.32
The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther (2008) 1.31
Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat Protoc (2010) 1.30
Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. Proc Natl Acad Sci U S A (2011) 1.28
FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. Am J Physiol Endocrinol Metab (2010) 1.26
Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum Gene Ther (2006) 1.25
Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Mol Ther (2012) 1.24
Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. Hum Gene Ther (2004) 1.22
A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol Ther (2007) 1.19
Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell (2002) 1.18
A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood (2002) 1.18
How do miRNAs mediate translational repression? Silence (2010) 1.17
Postintegrative gene silencing within the Sleeping Beauty transposition system. Mol Cell Biol (2007) 1.15
Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol (2005) 1.14